NLS Pharmaceutics Closes $500K Fundraising at Premium
Ticker: NCEL · Form: 6-K · Filed: Jan 8, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Jan 8, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $500,000, $1 Million, $3 |
| Sentiment | bullish |
Sentiment: bullish
Topics: fundraising, secondary-offering, pharmaceuticals
Related Tickers: NLS
TL;DR
NLS Pharma raised $500K at $3.10/share (48% premium) - looks good!
AI Summary
NLS Pharmaceutics Ltd. announced on January 8, 2025, the initial closing of a $500,000 fundraising, part of a previously announced $1 million total. This fundraising occurred at a share price of $3.10, which was 48% higher than the market share price on January 6, 2025. The company also noted the completion of its Extraordinary General Meeting.
Why It Matters
This fundraising at a premium to market price suggests investor confidence in NLS Pharmaceutics' future prospects, potentially providing capital for further development or operations.
Risk Assessment
Risk Level: medium — While the premium pricing is positive, the overall fundraising amount is relatively small, and the company's financial health and future funding needs remain a key consideration.
Key Numbers
- $500,000 — Initial Fundraising Closing (Represents the first tranche of capital raised.)
- $1 Million — Total Announced Fundraising (The full target amount for the current fundraising effort.)
- $3.10 — Share Price (The price per share at which the fundraising was conducted.)
- 48% — Premium to Market Price (Indicates investor willingness to pay above current market value.)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- Kadimastem Ltd. (company) — Partner in fundraising announcement
- $500,000 (dollar_amount) — Initial closing amount of fundraising
- $1 Million (dollar_amount) — Total announced fundraising amount
- $3.10 (dollar_amount) — Share price at which fundraising closed
- January 8, 2025 (date) — Date of press release and announcement
- January 6, 2025 (date) — Date for market share price comparison
FAQ
What is the total amount NLS Pharmaceutics Ltd. aims to raise in this fundraising round?
NLS Pharmaceutics Ltd. aims to raise a total of $1 Million in this fundraising round.
At what price did the initial closing of the fundraising occur?
The initial closing of the fundraising occurred at a share price of $3.10.
How does the fundraising share price compare to the market share price?
The fundraising share price of $3.10 represents 48% above the market share price as of January 6, 2025.
When was the press release announcing this fundraising issued?
The press release announcing this fundraising was issued on January 8, 2025.
What other company was mentioned in the announcement regarding the fundraising?
Kadimastem Ltd. was mentioned in the announcement regarding the fundraising.
Filing Stats: 269 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2025-01-08 08:04:51
Key Financial Figures
- $500,000 — em Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million
- $1 Million — of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extrao
- $3 — ary General Meeting at a Share Price of $3.10, Representing 48% Above the Market S
Filing Documents
- ea0227105-6k_nlspharma.htm (6-K) — 10KB
- ea022710501ex99-1_nlspharma.htm (EX-99.1) — 19KB
- 0001213900-25-001819.txt ( ) — 30KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: January 8, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2